Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell carcinoma No sarcomatoid, pure papillary, or Bellini renal cell cancer Measurable and/or evaluable disease Disease progression after at least 1 immunotherapy regimen for metastatic disease Localized metastases allowed provided the following are true: At least 3 months since prior treatment for metastases Not considered likely to influence outcome of transplantation No brain metastases unless treated surgically or radiologically and MRI normal Sufficiently healthy, HLA-compatible family member must be available as donor for patients undergoing stem cell transplantation PATIENT CHARACTERISTICS: Age 18 to 65 Performance status ECOG 0-1 Life expectancy More than 6 months Hematopoietic Platelet count at least 100,000/mm^3 Hepatic Transaminases less than 1.5 times upper limit of normal (ULN)* Bilirubin less than 1.5 times ULN* NOTE: *Unless due to Gilbert's disease Renal No renal insufficiency Calcium less than 10.4 mg/dL Creatinine clearance greater than 50 mL/min Cardiovascular Ejection fraction greater than 50% Pulmonary No DLCO that would preclude fludarabine or busulfan therapy Other Not pregnant or nursing Fertile patients must use effective contraception No physical obstacle to receiving study treatment No known autoimmune disease No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix No uncontrolled bacterial, viral, or fungal infection No prior or concurrent psychiatric disease HIV negative HTLV1 negative PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics Chemotherapy No tolerance to fludarabine and busulfan Endocrine therapy No concurrent corticosteroids Radiotherapy Not specified Surgery Not specified